I think the reason for the tempered response to the AE data is that, although it showed improvement, it still showed new AEs. My understanding is that AEs specifically pulmonary/coronary type AEs typically develop early in treatment. The fact that new ones continue occur in patients who have been on the drug for a significant time period is concerning and although dose reduction did help, New AEs still appear. This isn't a threat to the current approved indications but it is problematic for moving to earlier indications.
News 
Market Data 
Discover 
